title: Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results.
abstract: Recombinant adeno-associated virus (rAAV) vectors offer promise for the gene therapy of α(1)-antitrypsin (AAT) deficiency. In our prior trial, an rAAV vector expressing human AAT (rAAV1-CB-hAAT) provided sustained, vector-derived AAT expression for >1 year. In the current phase 2 clinical trial, this same vector, produced by a herpes simplex virus complementation method, was administered to nine AAT-deficient individuals by intramuscular injection at doses of 6.0×10(11), 1.9×10(12), and 6.0×10(12) vector genomes/kg (n=3 subjects/dose). Vector-derived expression of normal (M-type) AAT in serum was dose dependent, peaked on day 30, and persisted for at least 90 days. Vector administration was well tolerated, with only mild injection site reactions and no serious adverse events. Serum creatine kinase was transiently elevated on day 30 in five of six subjects in the two higher dose groups and normalized by day 45. As expected, all subjects developed anti-AAV antibodies and interferon-γ enzyme-linked immunospot responses to AAV peptides, and no subjects developed antibodies to AAT. One subject in the mid-dose group developed T cell responses to a single AAT peptide unassociated with any clinical effects. Muscle biopsies obtained on day 90 showed strong immunostaining for AAT and moderate to marked inflammatory cell infiltrates composed primarily of CD3-reactive T lymphocytes that were primarily of the CD8(+) subtype. These results support the feasibility and safety of AAV gene therapy for AAT deficiency, and indicate that serum levels of vector-derived normal human AAT >20 μg/ml can be achieved. However, further improvements in the design or delivery of rAAV-AAT vectors will be required to achieve therapeutic target serum AAT concentrations.
authors: University of Massachusetts Medical School, 55 Lake Avenue North,Worcester, MA 01655, USA. Terry.Flotte@umassmed.edu
authors: Terence R
authors: TR
authors: Flotte
authors: Bruce C
authors: BC
authors: Trapnell
authors: Margaret
authors: M
authors: Humphries
authors: Brenna
authors: B
authors: Carey
authors: Roberto
authors: R
authors: Calcedo
authors: Farshid
authors: F
authors: Rouhani
authors: Martha
authors: M
authors: Campbell-Thompson
authors: Anthony T
authors: AT
authors: Yachnis
authors: Robert A
authors: RA
authors: Sandhaus
authors: Noel G
authors: NG
authors: McElvaney
authors: Christian
authors: C
authors: Mueller
authors: Louis M
authors: LM
authors: Messina
authors: James M
authors: JM
authors: Wilson
authors: Mark
authors: M
authors: Brantly
authors: David R
authors: DR
authors: Knop
authors: Guo-jie
authors: GJ
authors: Ye
authors: Jeffrey D
authors: JD
authors: Chulay
references: J Virol. 1999 May;73(5):3994-4003
references: 10196295
references: J Gene Med. 2006 Jun;8(6):730-5
references: 16518879
references: Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11854-9
references: 12192090
references: Mol Ther. 2009 Jan;17(1):81-7
references: 18941444
references: Hum Gene Ther. 2006 Dec;17(12):1177-86
references: 17115945
references: Mol Ther. 2010 Jun;18(6):1165-72
references: 20372105
references: Hum Gene Ther. 2011 Feb;22(2):155-65
references: 20812844
references: Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16363-8
references: 19706466
references: Mol Ther. 2006 Jan;13(1):67-76
references: 16260185
references: Mol Ther. 2002 Sep;6(3):329-35
references: 12231168
references: Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2303-4
references: 18802015
references: Mol Ther. 2011 Jun;19(6):1070-8
references: 21364538
references: Mol Ther. 2000 Dec;2(6):619-23
references: 11124063
references: Blood. 2003 Apr 15;101(8):2963-72
references: 12515715
references: Hum Gene Ther. 2010 Oct;21(10):1343-8
references: 20497037
references: Chest. 1991 Sep;100(3):703-8
references: 1889260
references: Gene Ther. 1999 Jun;6(6):986-93
references: 10455400
references: Gene Ther. 2009 Feb;16(2):229-39
references: 18923452
references: Nat Biotechnol. 2010 Jan;28(1):79-82
references: 20037580
references: J Virol. 2002 Jan;76(2):791-801
references: 11752169
references: Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14384-8
references: 9826709
references: Mol Ther. 2008 Jul;16(7):1291-1299
references: 28178483
references: N Engl J Med. 2009 Jun 25;360(26):2749-57
references: 19553648
references: Nat Med. 2006 Mar;12(3):342-7
references: 16474400
references: Hum Gene Ther. 2009 Aug;20(8):861-70
references: 19419276
references: Mol Ther. 2010 Jan;18(1):151-60
references: 19888197
references: J Transl Med. 2007 Sep 24;5:45
references: 17892583